MAGNEVIST (brand of gadopentetate dimeglumine) Injection FOR INTRAVENOUS ADMINISTRATION

MAGNEVIST (brand of gadopentetate dimeglumine) Injection FOR INTRAVENOUS ADMINISTRATION Rx only WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

Generalized seizure after i.v. administration of gadopentetate dimeglumine.

Since its approval by the Food and Drug Administration , the use of gadopentetate dimeglumine (Magnevist; Berlex Laboratories, Wayne, NJ) for contrast-enhanced MR imaging has increased rapidly. To date, few reports of adverse anaphylactoid reactions related to use of this agent have been published (1 , 2] . Following is a report of a case of generalized seizure after IV administration of gadope...

Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.

For magnetic resonance, the established class of intravenous contrast media is the gadolinium-based contrast agents. In the 3 decades since initial approval, these have proven in general to be very safe for human administration. However, in 2006, a devastating late adverse reaction to administration of the less stable gadolinium-based contrast agents was identified, nephrogenic systemic fibrosi...

Bolus injection of MR contrast agents: hemodynamic effects evaluated by intracerebral laser Doppler flowmetry in rats.

PURPOSE To determine the effects on arterial blood pressure and cerebral blood flow of intravenous bolus injection of three MR contrast agents: gadopentetate dimeglumine, polylysine-Gd-DTPA, and superparamagnetic iron particles (SPIO). METHODS A single-fiber laser Doppler flowmetry probe was placed intracerebrally in 56 anesthetized rats. Cerebral blood flow and mean arterial blood pressure w...

Comparison of look-locker and MOLLI sequences for T1 mapping in hypertrophic and ischemic cardiomyopathy

Methods 5 control patients (4M/1F, age 44±21 y) with normal left ventricular (LV) function and no history of heart disease, 5 patients with ICM (3M/2F, 63±2 y), and 16 patients with HCM (10M/6F, age 51±15y) were recruited into an IRB approved protocol. All subjects were imaged at 1.5T (Achieva XR, Philips). T1 mapping was performed using MOLLI and LL at 2 LV short axis levels (basaland midcavit...